BIOLIFE SOLUTIONS INC (BLFS) Stock Fundamental Analysis
NASDAQ:BLFS - Nasdaq - US09062W2044 - Common Stock - Currency: USD
Taking everything into account, BLFS scores 4 out of 10 in our fundamental rating. BLFS was compared to 55 industry peers in the Life Sciences Tools & Services industry. BLFS has a great financial health rating, but its profitability evaluates not so good. BLFS is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
BLFS had negative earnings in the past year.
In the past year BLFS had a positive cash flow from operations.
BLFS had negative earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: BLFS reported negative operating cash flow in multiple years.
1.2 Ratios
With a Return On Assets value of -2.63%, BLFS perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
BLFS's Return On Equity of -2.95% is fine compared to the rest of the industry. BLFS outperforms 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -2.95% | ||
| ROIC | N/A |
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 62.64%, BLFS belongs to the top of the industry, outperforming 89.09% of the companies in the same industry.
BLFS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for BLFS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.64% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
2. Health
2.1 Basic Checks
BLFS does not have a ROIC to compare to the WACC, probably because it is not profitable.
BLFS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, BLFS has more shares outstanding
The debt/assets ratio for BLFS has been reduced compared to a year ago.
2.2 Solvency
BLFS has an Altman-Z score of 13.37. This indicates that BLFS is financially healthy and has little risk of bankruptcy at the moment.
BLFS has a better Altman-Z score (13.37) than 98.18% of its industry peers.
The Debt to FCF ratio of BLFS is 1.37, which is an excellent value as it means it would take BLFS, only 1.37 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of BLFS (1.37) is better than 87.27% of its industry peers.
BLFS has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
With a decent Debt to Equity ratio value of 0.01, BLFS is doing good in the industry, outperforming 69.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 1.37 | ||
| Altman-Z | 13.37 |
ROIC/WACCN/A
WACC8.81%
2.3 Liquidity
BLFS has a Current Ratio of 4.73. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
BLFS has a better Current ratio (4.73) than 69.09% of its industry peers.
BLFS has a Quick Ratio of 3.74. This indicates that BLFS is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.74, BLFS is in the better half of the industry, outperforming 65.45% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 4.73 | ||
| Quick Ratio | 3.74 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 72.64% over the past year.
Looking at the last year, BLFS shows a very negative growth in Revenue. The Revenue has decreased by -28.79% in the last year.
BLFS shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.59% yearly.
EPS 1Y (TTM)72.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.65%
Revenue 1Y (TTM)-28.79%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-24.54%
3.2 Future
Based on estimates for the next years, BLFS will show a very strong growth in Earnings Per Share. The EPS will grow by 44.23% on average per year.
BLFS is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.22% yearly.
EPS Next Y80.67%
EPS Next 2Y45.88%
EPS Next 3Y44.23%
EPS Next 5YN/A
Revenue Next Year-8.72%
Revenue Next 2Y3.56%
Revenue Next 3Y10.13%
Revenue Next 5Y16.22%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
BLFS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 318.70, which means the current valuation is very expensive for BLFS.
BLFS's Price/Forward Earnings ratio is in line with the industry average.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.21, BLFS is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 318.7 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of BLFS is on the same level as its industry peers.
The rest of the industry has a similar Price/Free Cash Flow ratio as BLFS.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 105.51 | ||
| EV/EBITDA | 250.78 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
A more expensive valuation may be justified as BLFS's earnings are expected to grow with 44.23% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y45.88%
EPS Next 3Y44.23%
5. Dividend
5.1 Amount
BLFS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
20.805
-0.46 (-2.14%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners102.55%
Inst Owner Change-1.75%
Ins Owners2.84%
Ins Owner Change2.65%
Market Cap995.31M
Analysts82.67
Price Target31.85 (53.09%)
Short Float %9.04%
Short Ratio7.7
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)288.97%
Min EPS beat(2)81.45%
Max EPS beat(2)496.49%
EPS beat(4)3
Avg EPS beat(4)96.58%
Min EPS beat(4)-246.6%
Max EPS beat(4)496.49%
EPS beat(8)6
Avg EPS beat(8)53.57%
EPS beat(12)7
Avg EPS beat(12)-13.03%
EPS beat(16)9
Avg EPS beat(16)-13.48%
Revenue beat(2)2
Avg Revenue beat(2)4.48%
Min Revenue beat(2)3.34%
Max Revenue beat(2)5.63%
Revenue beat(4)4
Avg Revenue beat(4)10.58%
Min Revenue beat(4)3.34%
Max Revenue beat(4)17.36%
Revenue beat(8)5
Avg Revenue beat(8)5.66%
Revenue beat(12)7
Avg Revenue beat(12)2.33%
Revenue beat(16)10
Avg Revenue beat(16)2.43%
PT rev (1m)0%
PT rev (3m)-0.35%
EPS NQ rev (1m)2.62%
EPS NQ rev (3m)20.64%
EPS NY rev (1m)0%
EPS NY rev (3m)28.39%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.08%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 318.7 | ||
| P/S | 10.56 | ||
| P/FCF | 105.51 | ||
| P/OCF | 68.02 | ||
| P/B | 2.82 | ||
| P/tB | 7.57 | ||
| EV/EBITDA | 250.78 |
EPS(TTM)-0.29
EYN/A
EPS(NY)0.07
Fwd EY0.31%
FCF(TTM)0.2
FCFY0.95%
OCF(TTM)0.31
OCFY1.47%
SpS1.97
BVpS7.37
TBVpS2.75
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -2.63% | ||
| ROE | -2.95% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 62.64% | ||
| FCFM | 10.01% |
ROA(3y)-17.53%
ROA(5y)-10.68%
ROE(3y)-21.44%
ROE(5y)-13.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28.1%
GM growth 5Y-0.79%
F-Score6
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 1.37 | ||
| Debt/EBITDA | 0.7 | ||
| Cap/Depr | 66.95% | ||
| Cap/Sales | 5.52% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 408.63% | ||
| Profit Quality | N/A | ||
| Current Ratio | 4.73 | ||
| Quick Ratio | 3.74 | ||
| Altman-Z | 13.37 |
F-Score6
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)80.15%
Cap/Depr(5y)101.86%
Cap/Sales(3y)10.07%
Cap/Sales(5y)11.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%95.65%
EPS Next Y80.67%
EPS Next 2Y45.88%
EPS Next 3Y44.23%
EPS Next 5YN/A
Revenue 1Y (TTM)-28.79%
Revenue growth 3Y-11.63%
Revenue growth 5Y24.59%
Sales Q2Q%-24.54%
Revenue Next Year-8.72%
Revenue Next 2Y3.56%
Revenue Next 3Y10.13%
Revenue Next 5Y16.22%
EBIT growth 1Y90.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year295.82%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y149.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y546.13%
OCF growth 3YN/A
OCF growth 5Y47.44%